Portrait of Kanav Jain

AI product leader and hands-on builder · Chicago · Open to relocation

I turn new AI capabilities into products that hospitals and other cautious institutions will deploy

calls on an average workday
300,000+
health systems using it
250+
since I left, still running
9 years

Doximity Dialer, which I originated as founding product lead. Doximity’s own figures, February 2026.

14 years as a product leader and hands-on builder, making products in clinical care, oncology and AI, after training in biomedical engineering and molecular-biology research. See where I’d fit →

The two products deal with one problem: records that go out of date while people still rely on them, like a guideline that no longer matches the evidence.

An illustrative NextConsensus claim record: at revision 4 the word “contested” is struck from “clinical benefit remains contested”, above the claim’s emerged, contested and authority dates
Illustrative record. At revision 4 an editor deletes “contested”, and a disputed claim reads as settled. NextConsensus keeps each revision with its date and source, so a team can see which claims are shedding their qualifiers and prepare documentation for them.

Commercial · in active development; the public site shows how a program works

NextConsensus

Tracks when medical evidence moves ahead of guidelines.

A terminal running “ambit approve” on an agent’s proposal: approved by Jordan, applicable true, with the note that the approval artifact is signed and expires
The agent drafted this change but had no way to apply it. It takes effect only when a named person approves, and the signed approval expires.

Experimental · open source, with a live demo and a roadmap that says what is not built

Ambit

Distinguishes the tools an agent can reach from the actions it is authorized to take.

  • Refract Records when a source changed and what changed. Live · open source, with a daily observation bot in production and a 16,146-edit public test set
  • Fast Harm, Slow Repair A draft test of how far an AI mistake spreads, and whether the fix reaches everyone it affected. Draft · 1 of 12 development cases built; no model results yet

Inspect the engineering: Ambit, Refract, and Stims →

I come in before there’s a roadmap, build an unproven idea far enough to see whether it holds, and then decide what to scale, what to cut, and who should own it.

I originated Doximity Dialer, led R&D at CancerCompass, and co-founded Andwise. Andwise showed in year one that physicians wanted it; I did not work out who would pay until year two, and by then every path that could fund growth made someone other than the physician the paying customer. I chose to wind down the company in 2024. Since then I have built NextConsensus, Ambit, and Refract, putting new AI capabilities into production alongside cross-functional teams.

Revised